Core Viewpoint - InMode (INMD) reported quarterly earnings of $0.70 per share, exceeding the Zacks Consensus Estimate of $0.57 per share, and showing an increase from $0.61 per share a year ago, representing an earnings surprise of 22.81% [1][2] Financial Performance - The company achieved revenues of $130.23 million for the quarter ended September 2024, surpassing the Zacks Consensus Estimate by 0.18% and up from $123.11 million year-over-year [2] - Over the last four quarters, InMode has consistently surpassed consensus EPS estimates and revenue estimates [2] Stock Performance - InMode shares have declined approximately 19.5% since the beginning of the year, contrasting with the S&P 500's gain of 22.3% [3] - The current Zacks Rank for InMode is 3 (Hold), indicating expected performance in line with the market in the near future [6] Earnings Outlook - The consensus EPS estimate for the upcoming quarter is $0.56 on revenues of $112.3 million, while the estimate for the current fiscal year is $1.78 on revenues of $409.1 million [7] - The trend of estimate revisions for InMode is currently mixed, which may change following the recent earnings report [6] Industry Context - The Medical - Products industry, to which InMode belongs, is currently ranked in the top 25% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8]

Core Insights - InMode Ltd. reported consolidated financial results for Q3 2024, showing a revenue increase of 5.8% year-over-year, reaching $130.2 million, despite challenges in demand and operational adjustments [2][5][4]. Financial Performance - Q3 2024 GAAP revenue was $130.2 million, including $31.9 million from pre-orders, compared to $123.1 million in Q3 2023 [2][5]. - Revenue from consumables and services decreased by 11% year-over-year to $15.8 million [2]. - GAAP operating income for Q3 2024 was $48.2 million, with a non-GAAP operating income of $52.2 million [2][8]. - The total cash position as of September 30, 2024, was $684.9 million, comprising cash, cash equivalents, marketable securities, and short-term bank deposits [2]. Profitability Metrics - GAAP net income for Q3 2024 was $51.0 million, or $0.65 per diluted share, compared to $46.5 million, or $0.54 per diluted share, in Q3 2023 [8][2]. - Non-GAAP net income for Q3 2024 was $55.0 million, or $0.70 per diluted share, compared to $53.1 million, or $0.61 per diluted share, in Q3 2023 [8][2]. Gross and Operating Margins - GAAP gross margin for Q3 2024 was 82%, down from 84% in Q3 2023 [6][7]. - GAAP operating margin for Q3 2024 was 37%, compared to 38% in Q3 2023, while non-GAAP operating margin was 40%, down from 43% [7]. 2024 Financial Outlook - The full-year 2024 revenue guidance has been revised to between $410 million and $420 million, down from the previous guidance of $430 million to $440 million [9]. - Non-GAAP gross margin is expected to be between 81% and 82%, and non-GAAP income from operations is projected to be between $140 million and $145 million [9].

Core Points - InMode Ltd. has been granted a preliminary injunction by the U.S. District Court for the Central District of California against sellers involved in the unlawful counterfeit sales of Morpheus8 radiofrequency devices and accessories [1] - The court's order includes a Temporary Restraining Order (TRO) due to strong evidence supporting the protection of InMode's trademarks and the public interest [1] - The injunction has resulted in the freezing of assets and account listings of the involved counterfeit sellers [1] Company Actions - InMode emphasizes its zero tolerance for dishonest business practices and prioritizes public safety [2] - The company plans to continue enforcement actions against sellers of counterfeit products to mitigate harm caused by these devices [2] - Patients can verify the authenticity of Morpheus8 devices by locating authorized providers through InMode's website [2] Company Overview - InMode is a leading global provider of innovative medical technologies, focusing on devices that utilize novel radiofrequency technology [3] - The company develops and markets a comprehensive line of products for various medical fields, including plastic surgery, gynecology, dermatology, otolaryngology, and ophthalmology [3] - More information about InMode's technologies can be found on their official website [3]

Wall Street expects a year-over-year decline in earnings on higher revenues when InMode (INMD) reports results for the quarter ended September 2024. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates.The earnings report, which is expected to be released on October 30, 2024, might help the stock move higher if these key numbers are better than expec ...

The proven Zacks Rank system focuses on earnings estimates and estimate revisions to find winning stocks. Nevertheless, we know that our readers all have their own perspectives, so we are always looking at the latest trends in value, growth, and momentum to find strong picks. Looking at the history of these trends, perhaps none is more beloved than value investing. This strategy simply looks to identify companies that are being undervalued by the broader market. Value investors use fundamental analysis and ...

Expects Q3 Revenue Between $130.0 Million -$130.1 Million (including $31.9 Million in Revenue from First Half of 2024 Pre-orders), Decreases Full Year 2024 Guidance to $410 Million-$420 Million Conference call to be held on Wednesday, October 30, 2024, at 8:30 a.m. Eastern Time YOKNEAM, Israel, Oct. 10, 2024 /PRNewswire/ -- InMode Ltd. (Nasdaq: INMD), a leading global provider of innovative medical technologies, announced today that it expects to release its financial results for the third quarter of 2024 b ...

Here at Zacks, we focus on our proven ranking system, which places an emphasis on earnings estimates and estimate revisions, to find winning stocks. But we also understand that investors develop their own strategies, so we are constantly looking at the latest trends in value, growth, and momentum to find strong companies for our readers. Of these, value investing is easily one of the most popular ways to find great stocks in any market environment. Value investors use fundamental analysis and traditional va ...

I specialize in biotech and healthcare investment analysis, integrating clinical expertise with a solid foundation in business strategy. My approach leverages detailed risk-return charts and DCF analyses to clearly communicate the investment potential and associated risks. I advocate for a barbell portfolio strategy, with 90% allocated to secure assets such as Treasuries and broad-market ETFs, and 10% to high-alpha stocks. This balanced approach ensures that all recommendations are made within a context of ...

Core Viewpoint - The article emphasizes the importance of value investing and highlights InMode (INMD) as a strong candidate for investors due to its attractive valuation metrics and strong earnings outlook [2][4][6]. Company Analysis - InMode (INMD) currently holds a Zacks Rank of 1 (Strong Buy) and a Value grade of A, indicating it is a top pick for value investors [4]. - The stock has a P/E ratio of 7.73, significantly lower than the industry average P/E of 21.64, suggesting it may be undervalued [4]. - Over the past 12 months, INMD's Forward P/E has fluctuated between 6.86 and 13.19, with a median of 8.37, further indicating its potential for value [4]. Valuation Metrics - InMode's P/B ratio stands at 1.75, which is attractive compared to the industry's average P/B of 5.22, reinforcing the notion of undervaluation [5]. - The P/B ratio for INMD has ranged from 1.73 to 4.91 over the past year, with a median of 2.37, highlighting its current favorable valuation [5]. Earnings Outlook - The combination of InMode's strong earnings outlook and its favorable valuation metrics positions it as an impressive value stock in the current market [6].

YOKNEAM, Israel, Sept. 10, 2024 /PRNewswire/ -- InMode Ltd. (Nasdaq: INMD), a leading global provider of innovative medical technologies, today announced that its Board of Directors has approved a share repurchase program of up to 7.68 million ordinary shares. "Following the completion of our share buyback program announced earlier this year, the board's authorization to enact this new share repurchase program demonstrates our ongoing confidence in the long-term outlook of the company," commented Moshe Mizr ...